NVS
154.12 USD
-1.11%
Today
-0.79%
1D
Market is closed
Sun
Closed
Mon
4:30 PM ~ 11:00 PM
Tue
4:30 PM ~ 11:00 PM
Wed
4:30 PM ~ 11:00 PM
Thu
4:30 PM ~ 11:00 PM
Fri
4:30 PM ~ 11:00 PM
Sat
Closed
Information
Name
Novartis AG Leveraged
Currency
USD
Standard Leverage
1X
Enhanced Leverage
3X
Overnight Fees Buy
-0.0191%
Overnight Fees Sell
0.0024%
Market Cap
297.32B
Avg Daily Volume
1.76M
52 Week High
170.46 USD
52 Week Low
97.72 USD
Trading Hours
See hours
Overnight Fees Calculator
| Daily Overnight Fee % | Daily Overnight Fee $ | |
|---|---|---|
| BUYS | -0.01910% | $(0.191) |
| SELLS | 0.00240% | $0.024 |
*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.
Business Summary
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Top News
Novartis
-0.79%
European Stocks Falling in Friday Trading as Investors Remain Jittery Over Middle East Conflict, Rising Oil Prices
finance.yahoo.com
2w ago
Novartis
-0.79%
European Stocks Dropping Sharply in Friday Trading; Middle East War Continues to Rattle Markets
finance.yahoo.com
3w ago
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
tradingview.com
1mo ago
Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.
